PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
ED  - Kimura, Yukiko
TI  - Treating Systemic Juvenile Idiopathic Arthritis: Now and in the Future
DP  - 2012  01
TA  - MD Conference Express
PG  - 27--28
VI  - 12
IP  - 19
4099  - http://mdc.sagepub.com/content/12/19/27.short
4100  - http://mdc.sagepub.com/content/12/19/27.full
AB  - Medication use patterns in systemic juvenile idiopathic arthritis (sJIA) are changing gradually and reflect significant treatment variability. Data from recent Phase 3 clinical trials of 2 biologic inhibiting agents, tocilizumab and canakinumab, may prompt further changes in treatment choices in the future, as these 2 agents show impressive response rates [Yokota S et al Lancet 2008; De Benedetti F et al. Arthritis Rheum 2010; De Benedetti F et al. Arthritis Rheum 2011; Brunner HI et al. ACR 2012 Abstract 759].